## Research-question validation

### Phenomenon-vs-method check

**Verdict**: pass

The question asks about the statistical relationship between specific vaccine types and adverse event categories, aiming to identify safety signals that deviate from background norms. It is framed around the phenomenon of reporting disproportionality rather than the performance of a specific machine learning architecture or a narrow computational constraint.

### Circularity check

**Verdict**: pass

The predictor variable is the vaccine type (COVID-19 vs. non-COVID) and the outcome is the reported adverse event category. These are distinct data fields within the VAERS database; the adverse events are not mathematically derived from the vaccine type, but rather reported as independent events following administration.

### Triviality check

**Verdict**: pass

A positive result identifying specific elevated signals would be a novel contribution to current safety monitoring, while a null result (finding no significant disproportionality after correction) would be a valuable, publishable finding that reinforces the safety profile of the vaccines relative to other vaccines. Both outcomes provide actionable epidemiological insights.

### Question-narrowing check

**Verdict**: pass

The question explicitly names a domain relationship: the comparison of adverse event rates between specific vaccine populations against background and non-COVID baselines. While the methodology sketch mentions CPU constraints, the research question itself does not hinge on whether a specific algorithm can run within a time limit, but rather on the statistical evidence found in the data.

### Overall verdict

**Verdict**: validated

The research question is well-posed, focusing on a substantive epidemiological inquiry regarding vaccine safety signals. It avoids circularity by comparing distinct data fields and avoids implementation narrowing by asking "what is the relationship" rather than "can method X find it." The project is ready to advance to initialization.
